You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《瑞通窩輪》【瑞通認股證牛熊證】微盟創新高後倒跌、資金續追最貼牛 京東迫近上周頂 恆指牛62319 熊54452/ 微盟全場最貼牛61687/ 京東牛58652 熊58711
阿思達克 12-30 10:50
美國加碼派錢議案在參議院遇挫,道指隔晚從紀錄高位回落,收報30335點,跌68點(或0.2%)。恆指昨收報26568點,升253點(或0.9%),盤中曾高見26618點。今早升勢持續,一度升超過300點,重返26900點。恆指好倉(牛證及認購權證)昨淨流出逾4500萬港元(下同),恆指淡倉(熊證及認沽權證)同日淨流入逾5100萬元,反映投資者預期大市將回軟。昨日恆指牛證街貨重貨區為收回價25900至25999點,而熊證街貨重貨區為收回價27300至27399點。

吉利汽車(00175)昨曾高見24.9元的逾兩年半高位,不過其後反覆偏軟,收跌2.6%於23.85元。吉利近日宣佈截至本月25日,其車款星瑞的累計訂單逾2.5萬輛,星瑞工廠產能按月提升40%。另據報吉利關聯企業組新公司,業務包括經營新能源汽車銷售。吉利今早回升逾2%,重上24.5元,即市留意25元關口阻力,下方留意10天線(約23.2元)的支持力度。昨有逾2300萬元淨流入其好倉,是最多資金淨流入的認股證相關資產,淡倉同日則有小量資金淨流出。

SaaS概念獲資金追捧,微盟(02013)延續近期強勢,昨曾飆8.5%至14.28元,創上市新高,全日維持4.2%升幅,收報13.72元,14日RSI升至70以上的超買水平。股份月內在成交增加下累升28.7%,已形成短期上升軌。今早曾再升逾4%,破頂高見14.36元,惟其後由高位調整,回至13.7元附近。昨有約1億元北水淨買入微盟,輪證資金流方面,逾40萬元淨流入其好倉。

2020年國家醫保藥品目錄談判工作結果出爐,醫藥股個別發展。中國生物製藥(01177)昨最多升3.8%至7.76元,收升2.4%於7.65元,收復50天線。股份在今月上旬獲集團創始人兼資深副主席謝炳三度增持,帶動股份由6.8元以下輾轉回升。今早靠穩,曾重上7.7元。昨分別有近220萬元和近10萬元淨流入其好倉和淡倉。

有報道傳京東集團(09618)旗下京東零售繼續進行新事業部整合,並宣布多名高層任命。另京東旗下子公司近日斥近8億元入股中國地利(01387),進軍農產品批發市場。京東昨曾升2%至324.8元,全日收升1.1%於322元,暫未能企穩20天線。京東今早再升逾3%,高位觸及334.6元,升穿50天線,短線阻力觀察上星期高位336.8元。昨有逾260萬元淨流出其好倉,淡倉同日亦有逾20萬元淨流出。

瑞通相關認股證之選擇:

吉利貼價、中短期購18565,行使價:25.73元,2021年5月到期,實際槓桿:4.4倍

吉利價外、中短期沽18580,行使價:19.9元,2021年5月到期,實際槓桿:4.2倍

微盟輕微價外、短期購23042,行使價:14.9元,2021年3月到期,實際槓桿:3.1倍

中藥貼價、中短期購22142,行使價:8.01元,2021年6月到期,實際槓桿:4.4倍

京東輕微價外、中短期購20460,行使價:388.888元,2021年4月到期,實際槓桿:6.1倍

京東輕微價外、短期沽18178,行使價:310.99元,2021年3月到期,實際槓桿:5.7倍

阿里輕微價外、中短期購18279,行使價:269.08元,2021年5月到期,實際槓桿:6.1倍

阿里輕微價外、中年期沽27517,行使價:212.88元,2021年7月到期,實際槓桿:3.6倍

比迪輕微價外、中年期購21243,行使價:228.88元,2021年6月到期,實際槓桿:3.7倍

瑞通相關牛熊證之選擇:

恆指牛證62319,收回價:26386點,槓桿比率:43.9倍

恆指熊證54452,收回價:27390點,槓桿比率:39.5倍

吉利牛證60748,收回價:22.68元,槓桿比率:10.2倍

吉利熊證56840,收回價:26.38元,槓桿比率:8.7倍

全場最貼微盟牛證61687,收回價:12.21元,槓桿比率:4.7倍

中藥牛證60148,收回價:6.81元,槓桿比率:5.4倍

京東牛證58652,收回價:312.3元,槓桿比率:9.5倍

京東熊證58711,收回價:362.88元,槓桿比率:8.2倍

阿里牛證66325,收回價:203.89元,槓桿比率:6.7倍

阿里熊證62329,收回價:246.88元,槓桿比率:14.9倍

比迪牛證60745,收回價:188.88元,槓桿比率:9.3倍

比迪熊證64986,收回價:228.88元,槓桿比率:4.9倍

重要風險通知

本結構性產品並無抵押品。

結構性產品之價格一般可急升亦可急跌,有可能損失結構性產品之全部或重大部分購買價,閣下對此應有所準備。

閣下投資前應了解產品風險,如有需要應諮詢專業建議。~

重要聲明:

以上資訊由第三方提供,AASTOCKS.com Limited對於任何包含於、經由、連結、下載或從任何與本網站有關服務所獲得之資訊、內容或廣告,不聲明或保證其內容之正確性或可靠性。對於您透過本網站上之廣告、資訊或要約而展示、購買或取得之任何產品、資訊資料,本公司亦不負品質保證之責任。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account